Stockreport

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com
PDF ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wear [Read more]